\-\ Texto\\:\\ \ \(0\)\
\-\ on\\ initial\\ exam\\,\\ the\\ patient\\ had\\ some\\ confusion\\ and\\ decreased\\ orientation\\ to\\ her\\ surroundings\\.\\ cranial\\ nerves\\ 2\\ through\\ 12\\ were\\ intact\\ bilaterally\\,\\ with\\ pupils\\ being\\ equal\\,\\ round\\ and\\ reactive\\ to\\ light\\ and\\ an\\ oropharynx\\ appearing\\ moist\\ and\\ clear\\ of\\ any\\ lesions\\;\\ jugular\\ venous\\ distension\\ was\\ not\\ noted\\.\\ chest\\ examination\\ revealed\\ an\\ elevated\\ heart\\ rate\\ of\\ greater\\ than\\ 95\\,\\ tachypnea\\ of\\ over\\ 20\\ breaths\\ per\\ minute\\ and\\ bilateral\\ rhonci\\ in\\ the\\ anterior\\ lung\\ fields\\.\\ abdominal\\ examination\\ was\\ unremarkable\\,\\ including\\ a\\ negative\\ hepatojugular\\ reflex\\,\\ and\\ the\\ lower\\ extremities\\ were\\ non\\-edematous\\ bilaterally\\.\\ the\\ patient\\ was\\ placed\\ on\\ 3\\ liters\\ of\\ oxygen\\ via\\ nasal\\ cannula\\ and\\ was\\ saturating\\ well\\ at\\ 96\\%\\ on\\ pulse\\ oximetry\\.\\ persistent\\ confusion\\ and\\ tachypnea\\,\\ however\\,\\ prompted\\ intubation\\ with\\ mechanical\\ ventilation\\.\ \(0\)\
\-\ \\*\\ following\\ the\\ above\\-described\\ plain\\ film\\ of\\ the\\ chest\\,\\ the\\ patient\\ underwent\\ bronchoscopy\\,\\ which\\ confirmed\\ diffuse\\ alveolar\\ hemorrhage\\ as\\ being\\ causative\\ of\\ the\\ abnormalities\\ seen\\ on\\ imaging\\.\\ moreover\\,\\ nursing\\ staff\\ noted\\ the\\ patient\\ to\\ be\\ anuric\\ with\\ a\\ serum\\ potassium\\ of\\ 7\\.3\\,\\ creatinine\\ of\\ 22\\.81\\,\\ but\\ no\\ evidence\\ of\\ structural\\ kidney\\ disease\\ on\\ renal\\ ultrasonography\\.\\ to\\ investigate\\ for\\ potential\\ autoimmune\\ vasculitis\\,\\ further\\ studies\\ were\\ performed\\,\\ which\\ included\\ serum\\ c3\\ of\\ 128\\,\\ c4\\ of\\ 104\\,\\ p\\-anca\\ staining\\ pattern\\ and\\ positive\\ anti\\-gbm\\ antibodies\\ of\\ \\>8\\.0\\ ai\\.\\ it\\ is\\ important\\ to\\ note\\ that\\ definitive\\ diagnosis\\ would\\ require\\ a\\ kidney\\ biopsy\\ with\\ demonstration\\ of\\ a\\ linear\\ immunofluorescence\\ pattern\\.\\ the\\ patient\\,\\ however\\,\\ declined\\ to\\ have\\ a\\ biopsy\\ performed\\ and\\ instead\\ opted\\ for\\ comfort\\ care\\.\ \(0\)\
\-\ the\\ patient\\ was\\ started\\ methylprednisolone\\ for\\ goodpasture\\ disease\\.\\ she\\ completed\\ 3\\ days\\ of\\ intravenous\\ methylprednisolone\\,\\ 1\\ gram\\ daily\\,\\ and\\ was\\ then\\ changed\\ to\\ both\\ prednisone\\,\\ 80\\ mg\\ daily\\ by\\ mouth\\,\\ and\\ cyclophosphamide\\,\\ 100\\ mg\\ daily\\ by\\ mouth\\,\\ both\\ of\\ which\\ she\\ was\\ given\\ for\\ a\\ total\\ of\\ 5\\ days\\.\\ simultaneously\\ with\\ cyclophosphamide\\ and\\ prednisone\\,\\ the\\ patient\\ completed\\ 5\\ days\\ of\\ plasmapharesis\\,\\ after\\ which\\ she\\ opted\\ for\\ comfort\\ care\\,\\ as\\ noted\\ above\\.\ \(0\)\
\-\ chest\\ x\\-ray\\ revealed\\ multifocal\\ patchy\\ and\\ nodular\\ opacities\\ throughout\\ both\\ lungs\\.\\ these\\ findings\\,\\ initially\\,\\ were\\ reported\\ to\\ be\\ consistent\\ with\\ either\\ multifocal\\ bronchopneumonia\\ or\\ underlying\\ malignancy\\ of\\ lungs\\,\\ either\\ from\\ primary\\ or\\ metastatic\\ disease\\.\\ another\\ condition\\ that\\ would\\ explain\\ these\\ findings\\,\\ although\\ less\\ common\\,\\ would\\ be\\ diffuse\\ alveolar\\ hemorrhage\\ secondary\\ to\\ autoimmune\\ vasculitis\\.\ \(0\)\
\-\ goodpasture\\ syndrome\ \(0\)\
\-\ the\\ differential\\ diagnosis\\ for\\ diffuse\\ alveolar\\ hemorrhage\\ includes\\:\ \(0\)\
\-\ general\\ medical\\ conditions\\:\ \(0\)\
\-\ pneumonia\ \(272\)\
\-\ malignancy\ \(256\)\
\-\ acute\\ respiratory\\ distress\\ syndrome\ \(0\)\
\-\ pulmonary\\ toxicity\\ from\\ cytotoxic\\ therapy\ \(0\)\
\-\ occurring\\ in\\ the\\ setting\\ of\\ pathologic\\ capilaritis\\:\ \(0\)\
\-\ immune\\ complex\\-mediated\\ vasculitis\\ \\(primary\\)\ \(0\)\
\-\ \\-\\>goodpasture\\ syndrome\ \(0\)\
\-\ \\-\\>henoch\\-schonlein\\ purpura\ \(0\)\
\-\ vasculitis\\ \\(secondary\\)\ \(0\)\
\-\ \\-\\>antiphospholipid\\ antibody\\ syndrome\ \(0\)\
\-\ \\-\\>dermatomyositis\\,\\ polymyositis\ \(0\)\
\-\ \\-\\>mixed\\ connective\\ tissue\\ disease\ \(0\)\
\-\ \\-\\>systemic\\ lupus\\ erythematosus\ \(0\)\
\-\ idiopathic\\ small\\ vessel\\ vasculitis\\ \\(primary\\)\ \(0\)\
\-\ \\-\\>churg\\-strauss\\ syndrome\ \(0\)\
\-\ \\-\\>microscopic\\ polyangitis\ \(0\)\
\-\ \\-\\>wegner\\'s\\ granulomatosis\ \(0\)\
\-\ occurring\\ outside\\ of\\ pathologic\\ capilaritis\\:\ \(0\)\
\-\ coagulopathy\\ \\(secondary\\ to\\ anti\\-platelet\\ therapy\\ or\\ dic\\,\\ for\\ example\\)\ \(0\)\
\-\ goodpasture\\ syndrome\ \(0\)\
\-\ idiopathic\\ pulmonary\\ hemosiderosis\ \(3\)\
\-\ reference\\:\\ park\\ ms\\ \\(2013\\)\\.\\ diffuse\\ alveolar\\ hemorrhage\\.\\ tuberc\\ respir\\ dis\\ \\(seoul\\)\\.\\ 74\\(4\\)\\:151\\-162\\.\ \(0\)\
\-\ the\\ patient\\ presented\\ to\\ the\\ hospital\\ with\\ four\\ weeks\\ of\\ sinusitis\\ and\\ progressive\\ dyspnea\\.\ \(0\)\
\-\ when\\ patients\\ present\\ with\\ multi\\-systemic\\ illness\\,\\ it\\ is\\ critical\\ to\\ evaluate\\ the\\ potential\\ for\\ a\\ single\\ disease\\ entity\\ as\\ being\\ causative\\ of\\ their\\ symptoms\\.\\ this\\ is\\ especially\\ true\\ in\\ the\\ case\\ of\\ diagnoses\\,\\ including\\ goodpasture\\ syndrome\\,\\ that\\ fall\\ under\\ the\\ category\\ of\\ autoimmune\\ vasculitis\\.\\ one\\ 2017\\ \\ study\\,\\ for\\ example\\,\\ described\\ a\\ 73\\ year\\-old\\ male\\ who\\ presented\\ with\\ small\\-volume\\ hemoptysis\\ and\\ went\\ on\\ to\\ develop\\ acute\\ kidney\\ injury\\ while\\ hospitalized\\.\\ he\\ was\\ discharged\\ with\\ diagnoses\\ of\\ both\\ acute\\ tubular\\ injury\\ and\\ interstitial\\ nephritis\\ secondary\\ to\\ the\\ receipt\\ of\\ cephalosporin\\,\\ only\\ to\\ return\\ in\\ two\\ days\\ with\\ diffuse\\ alveolar\\ hemorrhage\\.\\ a\\ kidney\\ biopsy\\ revealed\\ lymphocytic\\ proliferation\\ in\\ vessels\\ of\\ medium\\ size\\ along\\ with\\ non\\-caseating\\ granulomas\\ of\\ the\\ interstitium\\,\\ confirming\\ polyarteritis\\ nodosa\\ as\\ a\\ diagnosis\\Â\\¹\\.\\ the\\ case\\ presented\\ here\\ has\\ a\\ similar\\ teaching\\ point\\,\\ as\\ the\\ patient\\ presented\\ with\\ respiratory\\ distress\\ and\\ kidney\\ injury\\,\\ which\\ were\\ originally\\ considered\\ to\\ be\\ isolated\\ processes\\ but\\ were\\,\\ in\\ fact\\,\\ related\\ by\\ goodpasture\\ syndrome\\.\ \(0\)\
\-\ another\\ important\\ teaching\\ point\\ presented\\ by\\ this\\ case\\ is\\ that\\ of\\ evaluating\\ diffuse\\ alveolar\\ hemorrhage\\ clinically\\.\\ the\\ differential\\ diagnosis\\ for\\ diffuse\\ alveolar\\ hemorrhage\\,\\ already\\,\\ is\\ quite\\ broad\\,\\ and\\ notably\\ includes\\ a\\ variety\\ of\\ diseases\\ that\\ fall\\ under\\ the\\ classification\\ of\\ autoimmune\\ vasculitis\\,\\ including\\ goodpasture\\ syndrome\\,\\ as\\ discussed\\ in\\ this\\ case\\.\\ in\\ 2013\\,\\ a\\ researcher\\ published\\ in\\ tuberculosis\\ and\\ respiratory\\ diseases\\ an\\ algorithmic\\ approach\\ to\\ identifying\\ an\\ underlying\\ diagnosis\\ in\\ the\\ case\\ of\\ patients\\ presenting\\ with\\ diffuse\\ alveolar\\ hemorrhage\\.\\ the\\ first\\ steps\\ include\\ bronchoalveolar\\ lavage\\,\\ with\\ biopsy\\ and\\ culture\\ as\\ indicated\\,\\ and\\ clinical\\ history\\.\\ one\\ arm\\ of\\ the\\ algorithm\\ then\\ points\\ to\\ confirming\\ the\\ diagnosis\\ as\\ being\\ secondary\\ to\\ either\\ infection\\ or\\ malignancy\\,\\ while\\ the\\ other\\ arm\\ involves\\ a\\ full\\ rheumatologic\\ evaluation\\,\\ including\\ tests\\ for\\ antinuclear\\ antibody\\ \\(ana\\)\\,\\ anti\\-neutrophil\\ cytoplasmic\\ antibody\\ \\(anca\\)\\,\\ erythrocyte\\ sedimentation\\ rate\\ \\(esr\\)\\ and\\ even\\ anti\\-glomerular\\ basement\\ membrane\\ \\(gbm\\)\\ antibodies\\.\\ the\\ author\\ ultimately\\ concluded\\,\\ and\\ highlighted\\ using\\ this\\ algorithm\\,\\ that\\ most\\ diffuse\\ alveolar\\ hemorrhage\\ is\\,\\ in\\ fact\\,\\ caused\\ by\\ pulmonary\\ capillaritis\\ in\\ the\\ setting\\ of\\ systemic\\ vasculitis\\,\\ so\\ the\\ aforementioned\\ rheumatologic\\ workup\\ is\\ an\\ almost\\ essential\\ component\\ of\\ making\\ a\\ definitive\\ diagnosis\\Â\\²\\.\\ \ \(0\)\
\-\ another\\ retrospective\\ study\\ in\\ 2016\\ reported\\ similar\\ findings\\ across\\ six\\ clinical\\ cases\\ of\\ diffuse\\ alveolar\\ hemorrhage\\.\\ presenting\\ symptoms\\ varied\\,\\ but\\ included\\ renal\\ dysfunction\\,\\ hemoptysis\\,\\ hematuria\\ and\\ bleeding\\ from\\ mucosal\\ surfaces\\.\\ all\\ six\\ patients\\,\\ however\\,\\ had\\ documented\\ hypoxemia\\,\\ anemia\\ and\\ chest\\ cts\\ that\\ revealed\\ alveolar\\ filling\\ as\\ well\\ as\\ diffuse\\ infiltrates\\.\\ laboratory\\ studies\\ in\\ 5\\ of\\ 6\\ patients\\ revealed\\ elevated\\ c\\-reactive\\ protein\\ and\\ esr\\,\\ positive\\ serum\\ anca\\ in\\ 3\\ of\\ 6\\ cases\\ and\\ positive\\ anti\\-gbm\\ antibodies\\ in\\ 1\\ patient\\.\\ following\\ pathological\\ analysis\\,\\ 2\\ patients\\ with\\ diagnosed\\ with\\ microscopic\\ polyangiitis\\,\\ 2\\ more\\ with\\ granulomatosis\\ with\\ polyangiitis\\,\\ 1\\ with\\ pulmonary\\ veno\\-occlusive\\ disease\\,\\ and\\ 1\\ with\\ goodpasture\\ syndrome\\Â\\³\\.\\ this\\ study\\,\\ again\\,\\ points\\ to\\ an\\ association\\ between\\ diffuse\\ alveolar\\ hemorrhage\\ and\\ vasculitis\\,\\ and\\ to\\ the\\ importance\\ of\\ rheumatologic\\ laboratory\\ studies\\ in\\ evaluating\\ such\\ patients\\.\\ it\\ is\\ worth\\ noting\\,\\ however\\,\\ that\\ larger\\ studies\\ have\\ not\\ been\\ widely\\ conducted\\ in\\ order\\ to\\ test\\ the\\ strength\\ of\\ this\\ association\\,\\ and\\ more\\ research\\ is\\ warranted\\ before\\ the\\ institution\\ of\\ clinical\\ guidelines\\.\ \(0\)\
\-\ diffuse\\ alveolar\\ hemorrhage\\,\\ in\\ summary\\,\\ is\\ a\\ unique\\ clinical\\ entity\\ that\\ often\\ presents\\ in\\ the\\ setting\\ of\\ multi\\-systemic\\ illness\\.\\ its\\ presence\\ radiographically\\,\\ if\\ accompanied\\ by\\ kidney\\ injury\\,\\ should\\ prompt\\ consideration\\ of\\ and\\ workup\\ for\\ goodpasture\\ syndrome\\,\\ along\\ with\\ other\\ types\\ of\\ autoimmune\\ vasculitis\\.\ \(0\)\
\-\ references\\:\ \(0\)\
\-\ 1\\.\\	sitkin\\ na\\,\\ bernstein\\ e\\,\\ perazella\\ ma\\ \\(2017\\)\\.\\ atypical\\ case\\ of\\ classical\\ polyarteritis\\ nodosa\\:\\ alveolarhemorrhage\\ and\\ positive\\ antineutrophil\\ cytoplasmic\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ antibody\\.\\ clin\\ nephrol\\.\\ doi\\:10\\.5414\\/cn109156\\;\\ epub\\ ahead\\ of\\ print\\.\ \(0\)\
\-\ 2\\.\\	park\\ ms\\ \\(2013\\)\\.\\ diffuse\\ alveolar\\ hemorrhage\\.\\ tuberc\\ respir\\ dis\\ \\(seoul\\)\\.\\ 74\\(4\\)\\:151\\-162\\.\ \(0\)\
\-\ 3\\.\\	fang\\ f\\,\\ li\\ ym\\,\\ et\\ al\\ \\(2016\\)\\.\\ clinicopathological\\ diagnosis\\ of\\ diffuse\\ alveolar\\ hemorrhage\\.\\ zhonghua\\ yi\\ xue\\ za\\ zhi\\.\\ 96\\(2\\)\\:108\\-12\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ alveolar\\:\\ 0\\.05927900492558703\ \(0\)\
\-\ goodpasture\\:\\ 0\\.04603701975427797\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.03084399084311735\ \(0\)\
\-\ vasculitis\\:\\ 0\\.03048474400254503\ \(0\)\
\-\ diffuse\\:\\ 0\\.030058180716986616\ \(0\)\
\-\ \\-\\-\\:\\ 0\\.027363689900621768\ \(0\)\
\-\ \\>\\:\\ 0\\.02199200243740174\ \(0\)\
\-\ autoimmune\\:\\ 0\\.02110078463973673\ \(0\)\
\-\ syndrome\\:\\ 0\\.018930337542483668\ \(0\)\
\-\ \\,\\:\\ 0\\.018662428993833136\ \(0\)\
\-\ antibody\\:\\ 0\\.017598835656196278\ \(0\)\
\-\ rheumatologic\\:\\ 0\\.016745345882724392\ \(0\)\
\-\ antibodies\\:\\ 0\\.014352736857516434\ \(0\)\
\-\ kidney\\:\\ 0\\.01399093782362514\ \(0\)\
\-\ anti\\-gbm\\:\\ 0\\.01365688369320914\ \(0\)\
\-\ capilaritis\\:\\ 0\\.01365688369320914\ \(0\)\
\-\ tuberc\\:\\ 0\\.01365688369320914\ \(0\)\
\-\ seoul\\:\\ 0\\.01365688369320914\ \(0\)\
\-\ multi\\-systemic\\:\\ 0\\.01365688369320914\ \(0\)\
\-\ polyangiitis\\:\\ 0\\.01365688369320914\ \(0\)\
\-\ 2013\\:\\ 0\\.012660470783842036\ \(0\)\
\-\ algorithm\\:\\ 0\\.012583069315889315\ \(0\)\
\-\ respir\\:\\ 0\\.011954928172421981\ \(0\)\
\-\ methylprednisolone\\:\\ 0\\.011509254938569493\ \(0\)\
\-\ anca\\:\\ 0\\.011509254938569493\ \(0\)\
\-\ \\-idiopathic\\:\\ 0\\.010881113795102159\ \(0\)\
\-\ comfort\\:\\ 0\\.010642305615664113\ \(0\)\
\-\ park\\:\\ 0\\.010642305615664113\ \(0\)\
\-\ revealed\\:\\ 0\\.010621510030465117\ \(0\)\
\-\ polyarteritis\\:\\ 0\\.01043544056124967\ \(0\)\
\-\ that\\:\\ 0\\.010289563560828358\ \(0\)\
\-\ patients\\:\\ 0\\.010278425713552404\ \(0\)\
\-\ daily\\:\\ 0\\.010273592415090764\ \(0\)\
\-\ opted\\:\\ 0\\.010252972651634823\ \(0\)\
\-\ cytoplasmic\\:\\ 0\\.010252972651634823\ \(0\)\
\-\ setting\\:\\ 0\\.01002875775438319\ \(0\)\
\-\ as\\:\\ 0\\.010012219255570316\ \(0\)\
\-\ dis\\:\\ 0\\.009942096283761623\ \(0\)\
\-\ nodosa\\:\\ 0\\.009942096283761623\ \(0\)\
\-\ studies\\:\\ 0\\.009888461402878884\ \(0\)\
\-\ teaching\\:\\ 0\\.009807299417782337\ \(0\)\
\-\ causative\\:\\ 0\\.009683298321463921\ \(0\)\
\-\ serum\\:\\ 0\\.00958366508536953\ \(0\)\
\-\ cyclophosphamide\\:\\ 0\\.00956849123834429\ \(0\)\
\-\ including\\:\\ 0\\.009559778903153909\ \(0\)\
\-\ \\(\\:\\ 0\\.009512121879276242\ \(0\)\
\-\ 2017\\:\\ 0\\.009461608401029106\ \(0\)\
\-\ \\)\\:\\ 0\\.009395926232320826\ \(0\)\
\-\ biopsy\\:\\ 0\\.009393317557356347\ \(0\)\
\-\ secondary\\:\\ 0\\.009252633487640619\ \(0\)\
\-\ being\\:\\ 0\\.009226298921148129\ \(0\)\
\-\ 96\\:\\ 0\\.009179158274315003\ \(0\)\
\-\ diagnosis\\:\\ 0\\.009119532133758728\ \(0\)\
\-\ presented\\:\\ 0\\.009021524535330788\ \(0\)\
\-\ were\\:\\ 0\\.009017597227063924\ \(0\)\
\-\ points\\:\\ 0\\.008799417828098139\ \(0\)\
\-\ 2016\\:\\ 0\\.008733485040462513\ \(0\)\
\-\ case\\:\\ 0\\.00868863407994084\ \(0\)\
\-\ either\\:\\ 0\\.008648570619271267\ \(0\)\
\-\ positive\\:\\ 0\\.0085914348265968\ \(0\)\
\-\ another\\:\\ 0\\.008537230520829987\ \(0\)\
\-\ injury\\:\\ 0\\.00844061515689791\ \(0\)\
\-\ microscopic\\:\\ 0\\.008440313855894693\ \(0\)\
\-\ confirming\\:\\ 0\\.008387794023709283\ \(0\)\
\-\ granulomatosis\\:\\ 0\\.008287811806610026\ \(0\)\
\-\ respiratory\\:\\ 0\\.008243982025336568\ \(0\)\
\-\ clinical\\:\\ 0\\.008146583423907063\ \(0\)\
\-\ days\\:\\ 0\\.008114870011377158\ \(0\)\
\-\ entity\\:\\ 0\\.00810534389699518\ \(0\)\
\-\ confusion\\:\\ 0\\.007942120789856797\ \(0\)\
\-\ tachypnea\\:\\ 0\\.007866535717557134\ \(0\)\
\-\ prednisone\\:\\ 0\\.007830082584466205\ \(0\)\
\-\ diagnoses\\:\\ 0\\.007830082584466205\ \(0\)\
\-\ completed\\:\\ 0\\.007627727538119088\ \(0\)\
\-\ hemoptysis\\:\\ 0\\.007627727538119088\ \(0\)\
\-\ 74\\:\\ 0\\.007565751806726835\ \(0\)\
\-\ mouth\\:\\ 0\\.007448776512368749\ \(0\)\
\-\ occurring\\:\\ 0\\.007393442534673817\ \(0\)\
\-\ however\\:\\ 0\\.007372170582794951\ \(0\)\
\-\ illness\\:\\ 0\\.007366499478574871\ \(0\)\
\-\ evaluating\\:\\ 0\\.007366499478574871\ \(0\)\
\-\ example\\:\\ 0\\.007288372672026627\ \(0\)\
\-\ to\\:\\ 0\\.007277690461460649\ \(0\)\
\-\ mg\\:\\ 0\\.007263182089731072\ \(0\)\
\-\ multifocal\\:\\ 0\\.007120078572874348\ \(0\)\
\-\ ms\\:\\ 0\\.007075171466951417\ \(0\)\
\-\ would\\:\\ 0\\.007066538059849937\ \(0\)\
\-\ fact\\:\\ 0\\.006968288629636233\ \(0\)\
\-\ hepatojugular\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ saturating\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ 22\\.81\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ ai\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ plasmapharesis\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ \\-immune\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ complex\\-mediated\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ polyangitis\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ wegner\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ \\-coagulopathy\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ anti\\-platelet\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ \\-goodpasture\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ \\:151\\-162\\.\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ small\\-volume\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ receipt\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ cephalosporin\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ diagnosis\\Â\\¹\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ algorithmic\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ antinuclear\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ anti\\-glomerular\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ diagnosis\\Â\\²\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ syndrome\\Â\\³\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ sitkin\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ perazella\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ alveolarhemorrhage\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ doi\\:10\\.5414\\/cn109156\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ \\:151\\-162\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ fang\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ ym\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ zhonghua\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ yi\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ xue\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ za\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ zhi\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ \\:108\\-12\\:\\ 0\\.00682844184660457\ \(0\)\
\-\ workup\\:\\ 0\\.006811274695848025\ \(0\)\
\-\ for\\:\\ 0\\.006777147779792859\ \(0\)\
\-\ both\\:\\ 0\\.006761270304217262\ \(0\)\
\-\ esr\\:\\ 0\\.006703148031346799\ \(0\)\
\-\ diseases\\:\\ 0\\.0066687202439188985\ \(0\)\
\-\ patient\\:\\ 0\\.00663510403498364\ \(0\)\
\-\ by\\:\\ 0\\.006612877939170603\ \(0\)\
\-\ definitive\\:\\ 0\\.00653818524218731\ \(0\)\
\-\ study\\:\\ 0\\.0065336127580014535\ \(0\)\
\-\ in\\:\\ 0\\.006528229746557009\ \(0\)\
\-\ six\\:\\ 0\\.006507200475794328\ \(0\)\
\-\ disease\\:\\ 0\\.006491421570328601\ \(0\)\
\-\ association\\:\\ 0\\.0064323459796350605\ \(0\)\
\-\ potential\\:\\ 0\\.0063749621350489265\ \(0\)\
\-\ chest\\:\\ 0\\.006335333849907107\ \(0\)\
\-\ systemic\\:\\ 0\\.006333277467473521\ \(0\)\
\-\ 1\\:\\ 0\\.006300004238449905\ \(0\)\
\-\ surroundings\\:\\ 0\\.006291534657944658\ \(0\)\
\-\ rhonci\\:\\ 0\\.006291534657944658\ \(0\)\
\-\ anuric\\:\\ 0\\.006291534657944658\ \(0\)\
\-\ p\\-anca\\:\\ 0\\.006291534657944658\ \(0\)\
\-\ \\-vasculitis\\:\\ 0\\.006291534657944658\ \(0\)\
\-\ antiphospholipid\\:\\ 0\\.006291534657944658\ \(0\)\
\-\ dic\\:\\ 0\\.006291534657944658\ \(0\)\
\-\ researcher\\:\\ 0\\.006291534657944658\ \(0\)\
\-\ anti\\-neutrophil\\:\\ 0\\.006291534657944658\ \(0\)\
\-\ capillaritis\\:\\ 0\\.006291534657944658\ \(0\)\
\-\ veno\\-occlusive\\:\\ 0\\.006291534657944658\ \(0\)\
\-\ which\\:\\ 0\\.006177941856090429\ \(0\)\
\-\ \\:\\:\\ 0\\.006128523401963327\ \(0\)\
\-\ was\\:\\ 0\\.0061241054823466265\ \(0\)\
\-\ included\\:\\ 0\\.006104292952386285\ \(0\)\
\-\ breaths\\:\\ 0\\.005977464086210991\ \(0\)\
\-\ non\\-edematous\\:\\ 0\\.005977464086210991\ \(0\)\
\-\ above\\-described\\:\\ 0\\.005977464086210991\ \(0\)\
\-\ immunofluorescence\\:\\ 0\\.005977464086210991\ \(0\)\
\-\ \\-pneumonia\\:\\ 0\\.005977464086210991\ \(0\)\
\-\ henoch\\-schonlein\\:\\ 0\\.005977464086210991\ \(0\)\
\-\ churg\\-strauss\\:\\ 0\\.005977464086210991\ \(0\)\
\-\ non\\-caseating\\:\\ 0\\.005977464086210991\ \(0\)\
\-\ basement\\:\\ 0\\.005977464086210991\ \(0\)\
\-\ highlighted\\:\\ 0\\.005977464086210991\ \(0\)\
\-\ hypoxemia\\:\\ 0\\.005977464086210991\ \(0\)\
\-\ antineutrophil\\:\\ 0\\.005977464086210991\ \(0\)\
\-\ nephrol\\:\\ 0\\.005977464086210991\ \(0\)\
\-\ ahead\\:\\ 0\\.005977464086210991\ \(0\)\
\-\ clinicopathological\\:\\ 0\\.005977464086210991\ \(0\)\
\-\ important\\:\\ 0\\.0059469940845018185\ \(0\)\
\-\ primary\\:\\ 0\\.005882380161647629\ \(0\)\
\-\ fall\\:\\ 0\\.005823815055953819\ \(0\)\
\-\ 5\\:\\ 0\\.00580982282519945\ \(0\)\
\-\ pulmonary\\:\\ 0\\.005801433718559404\ \(0\)\
\-\ pathologic\\:\\ 0\\.005794492035217152\ \(0\)\
\-\ under\\:\\ 0\\.005784839750553114\ \(0\)\
\-\ point\\:\\ 0\\.005784839750553114\ \(0\)\
\-\ bronchopneumonia\\:\\ 0\\.0057546274692847465\ \(0\)\
\-\ polymyositis\\:\\ 0\\.0057546274692847465\ \(0\)\
\-\ bernstein\\:\\ 0\\.0057546274692847465\ \(0\)\
\-\ 2\\:\\ 0\\.005701330740543908\ \(0\)\
\-\ underlying\\:\\ 0\\.005673473012345034\ \(0\)\
\-\ 8\\.0\\:\\ 0\\.005581781960908132\ \(0\)\
\-\ simultaneously\\:\\ 0\\.005581781960908132\ \(0\)\
\-\ hemosiderosis\\:\\ 0\\.005581781960908132\ \(0\)\
\-\ distress\\:\\ 0\\.005577974696138672\ \(0\)\
\-\ she\\:\\ 0\\.005574251296950051\ \(0\)\
\-\ arm\\:\\ 0\\.005544657569537644\ \(0\)\
\-\ an\\:\\ 0\\.0054918583932675276\ \(0\)\
\-\ liters\\:\\ 0\\.0054405568975510795\ \(0\)\
\-\ cannula\\:\\ 0\\.0054405568975510795\ \(0\)\
\-\ presenting\\:\\ 0\\.005395506786523826\ \(0\)\
\-\ includes\\:\\ 0\\.005336762813073332\ \(0\)\
\-\ investigate\\:\\ 0\\.0053211528078320565\ \(0\)\
\-\ 128\\:\\ 0\\.0053211528078320565\ \(0\)\
\-\ \\-malignancy\\:\\ 0\\.0053211528078320565\ \(0\)\
\-\ \\-pulmonary\\:\\ 0\\.0053211528078320565\ \(0\)\
\-\ steps\\:\\ 0\\.0053211528078320565\ \(0\)\
\-\ epub\\:\\ 0\\.0053211528078320565\ \(0\)\
\-\ nephritis\\:\\ 0\\.005217720280624835\ \(0\)\
\-\ worth\\:\\ 0\\.005217720280624835\ \(0\)\
\-\ similar\\:\\ 0\\.005192388255524227\ \(0\)\
\-\ rate\\:\\ 0\\.005159909357824699\ \(0\)\
\-\ oximetry\\:\\ 0\\.005126486325817412\ \(0\)\
\-\ varied\\:\\ 0\\.005126486325817412\ \(0\)\
\-\ malignancy\\:\\ 0\\.005115553335091427\ \(0\)\
\-\ pattern\\:\\ 0\\.00506032895286023\ \(0\)\
\-\ moreover\\:\\ 0\\.005044874772248221\ \(0\)\
\-\ 7\\.3\\:\\ 0\\.005044874772248221\ \(0\)\
\-\ purpura\\:\\ 0\\.005044874772248221\ \(0\)\
\-\ lungs\\:\\ 0\\.005012840585562008\ \(0\)\
\-\ \\-acute\\:\\ 0\\.004971048141880811\ \(0\)\
\-\ published\\:\\ 0\\.004971048141880811\ \(0\)\
\-\ a\\:\\ 0\\.004915257032608537\ \(0\)\
\-\ dermatomyositis\\:\\ 0\\.004903649708891168\ \(0\)\
\-\ erythrocyte\\:\\ 0\\.004903649708891168\ \(0\)\
\-\ c\\-reactive\\:\\ 0\\.004903649708891168\ \(0\)\
\-\ print\\:\\ 0\\.004903649708891168\ \(0\)\
\-\ laboratory\\:\\ 0\\.0048785309618188475\ \(0\)\
\-\ reported\\:\\ 0\\.004825832456352924\ \(0\)\
\-\ nursing\\:\\ 0\\.004784245619172145\ \(0\)\
\-\ staff\\:\\ 0\\.004784245619172145\ \(0\)\
\-\ interstitium\\:\\ 0\\.004784245619172145\ \(0\)\
\-\ lavage\\:\\ 0\\.004784245619172145\ \(0\)\
\-\ aforementioned\\:\\ 0\\.004784245619172145\ \(0\)\
\-\ cts\\:\\ 0\\.004784245619172145\ \(0\)\
\-\ care\\:\\ 0\\.004774867772376069\ \(0\)\
\-\ and\\:\\ 0\\.004740748408129688\ \(0\)\
\-\ medium\\:\\ 0\\.004730804200514553\ \(0\)\
\-\ bronchoalveolar\\:\\ 0\\.004730804200514553\ \(0\)\
\-\ author\\:\\ 0\\.004730804200514553\ \(0\)\
\-\ concluded\\:\\ 0\\.004730804200514553\ \(0\)\
\-\ noting\\:\\ 0\\.004730804200514553\ \(0\)\
\-\ then\\:\\ 0\\.004711025373233292\ \(0\)\
\-\ noted\\:\\ 0\\.004706633280679923\ \(0\)\
\-\ 104\\:\\ 0\\.004680813091964924\ \(0\)\
\-\ explain\\:\\ 0\\.004680813091964924\ \(0\)\
\-\ notably\\:\\ 0\\.004680813091964924\ \(0\)\
\-\ summary\\:\\ 0\\.004680813091964924\ \(0\)\
\-\ classical\\:\\ 0\\.004680813091964924\ \(0\)\
\-\ 3\\:\\ 0\\.004649826940448969\ \(0\)\
\-\ potassium\\:\\ 0\\.004633853663756997\ \(0\)\
\-\ toxicity\\:\\ 0\\.004633853663756997\ \(0\)\
\-\ retrospective\\:\\ 0\\.004633853663756997\ \(0\)\
\-\ guidelines\\:\\ 0\\.004633853663756997\ \(0\)\
\-\ declined\\:\\ 0\\.004547699027730487\ \(0\)\
\-\ hospitalized\\:\\ 0\\.004547699027730487\ \(0\)\
\-\ ma\\:\\ 0\\.004547699027730487\ \(0\)\
\-\ erythematosus\\:\\ 0\\.0045079675835883095\ \(0\)\
\-\ ana\\:\\ 0\\.0045079675835883095\ \(0\)\
\-\ elevated\\:\\ 0\\.004491582279409857\ \(0\)\
\-\ cytotoxic\\:\\ 0\\.004470175047438478\ \(0\)\
\-\ research\\:\\ 0\\.004470175047438478\ \(0\)\
\-\ this\\:\\ 0\\.004466942896889851\ \(0\)\
\-\ it\\:\\ 0\\.00446362908876766\ \(0\)\
\-\ sedimentation\\:\\ 0\\.0044341409532209\ \(0\)\
\-\ cases\\:\\ 0\\.004410241462402994\ \(0\)\
\-\ minute\\:\\ 0\\.0043997089140490695\ \(0\)\
\-\ staining\\:\\ 0\\.0043997089140490695\ \(0\)\
\-\ along\\:\\ 0\\.0043749866411441\ \(0\)\
\-\ widely\\:\\ 0\\.004366742520231256\ \(0\)\
\-\ conducted\\:\\ 0\\.004366742520231256\ \(0\)\
\-\ is\\:\\ 0\\.004355466912352638\ \(0\)\
\-\ bilaterally\\:\\ 0\\.00434811036177212\ \(0\)\
\-\ category\\:\\ 0\\.004335122075211695\ \(0\)\
\-\ ultrasonography\\:\\ 0\\.0043047419720720495\ \(0\)\
\-\ surfaces\\:\\ 0\\.0043047419720720495\ \(0\)\
\-\ c4\\:\\ 0\\.0042755085654238335\ \(0\)\
\-\ demonstration\\:\\ 0\\.0042755085654238335\ \(0\)\
\-\ granulomas\\:\\ 0\\.004247338430512234\ \(0\)\
\-\ of\\:\\ 0\\.004241424196363638\ \(0\)\
\-\ but\\:\\ 0\\.0042350967491096925\ \(0\)\
\-\ findings\\:\\ 0\\.004226576922827172\ \(0\)\
\-\ orientation\\:\\ 0\\.004220156927947347\ \(0\)\
\-\ intubation\\:\\ 0\\.004220156927947347\ \(0\)\
\-\ structural\\:\\ 0\\.004220156927947347\ \(0\)\
\-\ lymphocytic\\:\\ 0\\.004220156927947347\ \(0\)\
\-\ unique\\:\\ 0\\.004220156927947347\ \(0\)\
\-\ differential\\:\\ 0\\.004202881222855042\ \(0\)\
\-\ moist\\:\\ 0\\.004193897011854642\ \(0\)\
\-\ c3\\:\\ 0\\.004193897011854642\ \(0\)\
\-\ changed\\:\\ 0\\.004193897011854642\ \(0\)\
\-\ essential\\:\\ 0\\.004193897011854642\ \(0\)\
\-\ warranted\\:\\ 0\\.004193897011854642\ \(0\)\
\-\ instead\\:\\ 0\\.004168498233525447\ \(0\)\
\-\ while\\:\\ 0\\.004165219581490803\ \(0\)\
\-\ oropharynx\\:\\ 0\\.004143905903305013\ \(0\)\
\-\ identifying\\:\\ 0\\.004143905903305013\ \(0\)\
\-\ prompted\\:\\ 0\\.004120070381487233\ \(0\)\
\-\ critical\\:\\ 0\\.004120070381487233\ \(0\)\
\-\ infiltrates\\:\\ 0\\.004120070381487233\ \(0\)\
\-\ examination\\:\\ 0\\.004115295175018692\ \(0\)\
\-\ gram\\:\\ 0\\.0040969464750970856\ \(0\)\
\-\ be\\:\\ 0\\.00408290231864889\ \(0\)\
\-\ bronchoscopy\\:\\ 0\\.0040744929221356195\ \(0\)\
\-\ 73\\:\\ 0\\.0040744929221356195\ \(0\)\
\-\ accompanied\\:\\ 0\\.0040744929221356195\ \(0\)\
\-\ prompt\\:\\ 0\\.0040744929221356195\ \(0\)\
\-\ ventilation\\:\\ 0\\.004031448885609817\ \(0\)\
\-\ proliferation\\:\\ 0\\.0039906714003383826\ \(0\)\
\-\ quite\\:\\ 0\\.0039906714003383826\ \(0\)\
\-\ renal\\:\\ 0\\.003977498914729774\ \(0\)\
\-\ documented\\:\\ 0\\.003971060394928398\ \(0\)\
\-\ the\\:\\ 0\\.003962218074387416\ \(0\)\
\-\ 6\\:\\ 0\\.003953710552091208\ \(0\)\
\-\ already\\:\\ 0\\.003933267858778567\ \(0\)\
\-\ e\\:\\ 0\\.003933267858778567\ \(0\)\
\-\ variety\\:\\ 0\\.0039150412922331025\ \(0\)\
\-\ gbm\\:\\ 0\\.0039150412922331025\ \(0\)\
\-\ connective\\:\\ 0\\.003897233764560989\ \(0\)\
\-\ lupus\\:\\ 0\\.003897233764560989\ \(0\)\
\-\ clin\\:\\ 0\\.003897233764560989\ \(0\)\
\-\ membrane\\:\\ 0\\.003879826440120975\ \(0\)\
\-\ ultimately\\:\\ 0\\.0038628017253891584\ \(0\)\
\-\ pathological\\:\\ 0\\.0038628017253891584\ \(0\)\
\-\ importance\\:\\ 0\\.0038628017253891584\ \(0\)\
\-\ distension\\:\\ 0\\.003846143162088645\ \(0\)\
\-\ sinusitis\\:\\ 0\\.003829835331571346\ \(0\)\
\-\ jugular\\:\\ 0\\.0037982148865517832\ \(0\)\
\-\ oxygen\\:\\ 0\\.0037982148865517832\ \(0\)\
\-\ classification\\:\\ 0\\.0037828759033634177\ \(0\)\
\-\ creatinine\\:\\ 0\\.0037678347834121384\ \(0\)\
\-\ following\\:\\ 0\\.0037572079890025537\ \(0\)\
\-\ originally\\:\\ 0\\.0037386013767639224\ \(0\)\
\-\ 95\\:\\ 0\\.0037243882561843744\ \(0\)\
\-\ consideration\\:\\ 0\\.0036967212673369083\ \(0\)\
\-\ performed\\:\\ 0\\.003691058607633337\ \(0\)\
\-\ 4\\:\\ 0\\.0036885699538017746\ \(0\)\
\-\ \\*\\:\\ 0\\.0036832497392874355\ \(0\)\
\-\ making\\:\\ 0\\.0036700085050819357\ \(0\)\
\-\ mechanical\\:\\ 0\\.0036569898231947314\ \(0\)\
\-\ radiographically\\:\\ 0\\.0036569898231947314\ \(0\)\
\-\ true\\:\\ 0\\.003631591044865536\ \(0\)\
\-\ pupils\\:\\ 0\\.0036191972870449\ \(0\)\
\-\ discussed\\:\\ 0\\.0036191972870449\ \(0\)\
\-\ fields\\:\\ 0\\.0036069987146451015\ \(0\)\
\-\ reflex\\:\\ 0\\.0036069987146451015\ \(0\)\
\-\ institution\\:\\ 0\\.0036069987146451015\ \(0\)\
\-\ one\\:\\ 0\\.003587500206523074\ \(0\)\
\-\ processes\\:\\ 0\\.0035831631928273217\ \(0\)\
\-\ na\\:\\ 0\\.00357151495319561\ \(0\)\
\-\ reference\\:\\ 0\\.003560039286437174\ \(0\)\
\-\ patchy\\:\\ 0\\.003548731153655491\ \(0\)\
\-\ therapy\\:\\ 0\\.003539335083254242\ \(0\)\
\-\ across\\:\\ 0\\.0035375857334757083\ \(0\)\
\-\ went\\:\\ 0\\.0035265984097019236\ \(0\)\
\-\ culture\\:\\ 0\\.0035265984097019236\ \(0\)\
\-\ dysfunction\\:\\ 0\\.0035265984097019236\ \(0\)\
\-\ li\\:\\ 0\\.0035265984097019236\ \(0\)\
\-\ approach\\:\\ 0\\.003473884650410664\ \(0\)\
\-\ equal\\:\\ 0\\.0034637591031082995\ \(0\)\
\-\ tests\\:\\ 0\\.0034637591031082995\ \(0\)\
\-\ opacities\\:\\ 0\\.003453764211678472\ \(0\)\
\-\ here\\:\\ 0\\.003453764211678472\ \(0\)\
\-\ f\\:\\ 0\\.003453764211678472\ \(0\)\
\-\ these\\:\\ 0\\.003445150568486197\ \(0\)\
\-\ isolated\\:\\ 0\\.0034438966471723293\ \(0\)\
\-\ broad\\:\\ 0\\.003434153206268487\ \(0\)\
\-\ pulse\\:\\ 0\\.003415026473045891\ \(0\)\
\-\ mucosal\\:\\ 0\\.003415026473045891\ \(0\)\
\-\ protein\\:\\ 0\\.0033963606701186556\ \(0\)\
\-\ types\\:\\ 0\\.0033781341035731918\ \(0\)\
\-\ analysis\\:\\ 0\\.003369179167553768\ \(0\)\
\-\ on\\:\\ 0\\.003364326935857915\ \(0\)\
\-\ nerves\\:\\ 0\\.003360326575901078\ \(0\)\
\-\ return\\:\\ 0\\.0033515740156733996\ \(0\)\
\-\ 100\\:\\ 0\\.003342919251461064\ \(0\)\
\-\ order\\:\\ 0\\.0033175204731318688\ \(0\)\
\-\ more\\:\\ 0\\.0033108850647748512\ \(0\)\
\-\ develop\\:\\ 0\\.0033010391420340494\ \(0\)\
\-\ symptoms\\:\\ 0\\.0032992369897724854\ \(0\)\
\-\ conditions\\:\\ 0\\.003292928142911435\ \(0\)\
\-\ anemia\\:\\ 0\\.003292928142911435\ \(0\)\
\-\ intravenous\\:\\ 0\\.003284901197105434\ \(0\)\
\-\ nasal\\:\\ 0\\.003276956580399633\ \(0\)\
\-\ acute\\:\\ 0\\.0032685969467180407\ \(0\)\
\-\ interstitial\\:\\ 0\\.0032384116465816134\ \(0\)\
\-\ almost\\:\\ 0\\.0032016941881040113\ \(0\)\
\-\ larger\\:\\ 0\\.0031874810675244633\ \(0\)\
\-\ again\\:\\ 0\\.003180471125216239\ \(0\)\
\-\ vessel\\:\\ 0\\.0031530490283526325\ \(0\)\
\-\ tuberculosis\\:\\ 0\\.0031530490283526325\ \(0\)\
\-\ hematuria\\:\\ 0\\.0031396936399448044\ \(0\)\
\-\ \\;\\:\\ 0\\.0031377555204532824\ \(0\)\
\-\ reactive\\:\\ 0\\.0031331013164220245\ \(0\)\
\-\ dyspnea\\:\\ 0\\.0031331013164220245\ \(0\)\
\-\ 80\\:\\ 0\\.0031136544371570545\ \(0\)\
\-\ or\\:\\ 0\\.0031030913988031217\ \(0\)\
\-\ light\\:\\ 0\\.0030884621895152574\ \(0\)\
\-\ tubular\\:\\ 0\\.0030822900983849886\ \(0\)\
\-\ involves\\:\\ 0\\.0030761667989991537\ \(0\)\
\-\ other\\:\\ 0\\.0030513377981447693\ \(0\)\
\-\ discharged\\:\\ 0\\.0030346077645356986\ \(0\)\
\-\ require\\:\\ 0\\.0030288486797273965\ \(0\)\
\-\ component\\:\\ 0\\.0030231320977772633\ \(0\)\
\-\ so\\:\\ 0\\.0030118239649955802\ \(0\)\
\-\ well\\:\\ 0\\.0029947032578910163\ \(0\)\
\-\ x\\-ray\\:\\ 0\\.0029842554560082037\ \(0\)\
\-\ started\\:\\ 0\\.0029524183718210996\ \(0\)\
\-\ even\\:\\ 0\\.002947237126158205\ \(0\)\
\-\ from\\:\\ 0\\.0029429180011329484\ \(0\)\
\-\ appearing\\:\\ 0\\.0029420903076309633\ \(0\)\
\-\ strength\\:\\ 0\\.002936977461750753\ \(0\)\
\-\ mixed\\:\\ 0\\.002906989458512418\ \(0\)\
\-\ clinically\\:\\ 0\\.002902102418083863\ \(0\)\
\-\ per\\:\\ 0\\.002897246017608576\ \(0\)\
\-\ their\\:\\ 0\\.002897246017608576\ \(0\)\
\-\ cranial\\:\\ 0\\.0028781192843859798\ \(0\)\
\-\ four\\:\\ 0\\.0028734104957907963\ \(0\)\
\-\ using\\:\\ 0\\.0028734104957907963\ \(0\)\
\-\ bleeding\\:\\ 0\\.0028734104957907963\ \(0\)\
\-\ atypical\\:\\ 0\\.002868730159264102\ \(0\)\
\-\ have\\:\\ 0\\.002866674017606649\ \(0\)\
\-\ indicated\\:\\ 0\\.0028640779330362074\ \(0\)\
\-\ round\\:\\ 0\\.0028594534814587445\ \(0\)\
\-\ full\\:\\ 0\\.0028594534814587445\ \(0\)\
\-\ had\\:\\ 0\\.002856467574346566\ \(0\)\
\-\ total\\:\\ 0\\.002850286589400648\ \(0\)\
\-\ via\\:\\ 0\\.0028412269149132806\ \(0\)\
\-\ test\\:\\ 0\\.0028278330364391825\ \(0\)\
\-\ described\\:\\ 0\\.002819030744688357\ \(0\)\
\-\ linear\\:\\ 0\\.002806012062801153\ \(0\)\
\-\ al\\:\\ 0\\.002806012062801153\ \(0\)\
\-\ before\\:\\ 0\\.0028017206759881276\ \(0\)\
\-\ general\\:\\ 0\\.002788987348069336\ \(0\)\
\-\ nodular\\:\\ 0\\.0027764599590332393\ \(0\)\
\-\ outside\\:\\ 0\\.0027764599590332393\ \(0\)\
\-\ caused\\:\\ 0\\.0027764599590332393\ \(0\)\
\-\ condition\\:\\ 0\\.0027682195266513212\ \(0\)\
\-\ references\\:\\ 0\\.0027519970837038056\ \(0\)\
\-\ related\\:\\ 0\\.002732185432433744\ \(0\)\
\-\ especially\\:\\ 0\\.002724400509231961\ \(0\)\
\-\ 12\\:\\ 0\\.002709061526043596\ \(0\)\
\-\ et\\:\\ 0\\.002709061526043596\ \(0\)\
\-\ initially\\:\\ 0\\.002694020406092316\ \(0\)\
\-\ single\\:\\ 0\\.0026829281878314733\ \(0\)\
\-\ placed\\:\\ 0\\.0026792658011576187\ \(0\)\
\-\ evaluate\\:\\ 0\\.0026756206493083446\ \(0\)\
\-\ considered\\:\\ 0\\.0026719925708324145\ \(0\)\
\-\ vessels\\:\\ 0\\.0026647869994441\ \(0\)\
\-\ filling\\:\\ 0\\.0026647869994441\ \(0\)\
\-\ persistent\\:\\ 0\\.002640082612320976\ \(0\)\
\-\ progressive\\:\\ 0\\.002616141839692721\ \(0\)\
\-\ extremities\\:\\ 0\\.0025961941277621134\ \(0\)\
\-\ note\\:\\ 0\\.0025546595875304344\ \(0\)\
\-\ film\\:\\ 0\\.002542315209325312\ \(0\)\
\-\ its\\:\\ 0\\.0024977005758757874\ \(0\)\
\-\ hospital\\:\\ 0\\.0024919414910674854\ \(0\)\
\-\ confirmed\\:\\ 0\\.0024890779264808657\ \(0\)\
\-\ greater\\:\\ 0\\.0024862249091173517\ \(0\)\
\-\ throughout\\:\\ 0\\.002477728370487937\ \(0\)\
\-\ clear\\:\\ 0\\.0024473482673482926\ \(0\)\
\-\ diagnosed\\:\\ 0\\.0024339234367118556\ \(0\)\
\-\ intact\\:\\ 0\\.002431266167078402\ \(0\)\
\-\ abnormalities\\:\\ 0\\.002431266167078402\ \(0\)\
\-\ year\\-old\\:\\ 0\\.002431266167078402\ \(0\)\
\-\ above\\:\\ 0\\.002425978820006055\ \(0\)\
\-\ venous\\:\\ 0\\.002402622477503586\ \(0\)\
\-\ presence\\:\\ 0\\.002402622477503586\ \(0\)\
\-\ 20\\:\\ 0\\.002379949834358649\ \(0\)\
\-\ heart\\:\\ 0\\.002299829317512606\ \(0\)\
\-\ underwent\\:\\ 0\\.002271259516249589\ \(0\)\
\-\ given\\:\\ 0\\.0022691048741412412\ \(0\)\
\-\ 3\\.\\:\\ 0\\.0022648134873282165\ \(0\)\
\-\ less\\:\\ 0\\.0022416266493591654\ \(0\)\
\-\ although\\:\\ 0\\.002235421596108911\ \(0\)\
\-\ first\\:\\ 0\\.0022211335668364464\ \(0\)\
\-\ size\\:\\ 0\\.0022191137655916122\ \(0\)\
\-\ initial\\:\\ 0\\.002193324665592028\ \(0\)\
\-\ unremarkable\\:\\ 0\\.0021913760020775067\ \(0\)\
\-\ plain\\:\\ 0\\.002149700784422219\ \(0\)\
\-\ often\\:\\ 0\\.0021119082482723875\ \(0\)\
\-\ should\\:\\ 0\\.0021101537892244775\ \(0\)\
\-\ further\\:\\ 0\\.002104914129976962\ \(0\)\
\-\ 2\\.\\:\\ 0\\.002104914129976962\ \(0\)\
\-\ between\\:\\ 0\\.0020979825997089418\ \(0\)\
\-\ any\\:\\ 0\\.0020843028916129307\ \(0\)\
\-\ such\\:\\ 0\\.0020691965839201025\ \(0\)\
\-\ 1\\.\\:\\ 0\\.002067536147403254\ \(0\)\
\-\ medical\\:\\ 0\\.0020366458559767657\ \(0\)\
\-\ some\\:\\ 0\\.0020100141393235935\ \(0\)\
\-\ with\\:\\ 0\\.001993874418263032\ \(0\)\
\-\ her\\:\\ 0\\.0019902491545197025\ \(0\)\
\-\ only\\:\\ 0\\.0019902491545197025\ \(0\)\
\-\ negative\\:\\ 0\\.001976855276045604\ \(0\)\
\-\ decreased\\:\\ 0\\.001968052984294779\ \(0\)\
\-\ infection\\:\\ 0\\.001924102690993654\ \(0\)\
\-\ evaluation\\:\\ 0\\.0019227256358069775\ \(0\)\
\-\ lung\\:\\ 0\\.001917241766257743\ \(0\)\
\-\ not\\:\\ 0\\.0019129646347667475\ \(0\)\
\-\ when\\:\\ 0\\.0018956864737536838\ \(0\)\
\-\ two\\:\\ 0\\.0018956864737536838\ \(0\)\
\-\ through\\:\\ 0\\.0018799047392880472\ \(0\)\
\-\ weeks\\:\\ 0\\.0018786039945012769\ \(0\)\
\-\ all\\:\\ 0\\.0018721328345711007\ \(0\)\
\-\ include\\:\\ 0\\.0018568191231838008\ \(0\)\
\-\ he\\:\\ 0\\.0018467756328683343\ \(0\)\
\-\ been\\:\\ 0\\.0018007706347513489\ \(0\)\
\-\ if\\:\\ 0\\.0017960832174908098\ \(0\)\
\-\ lesions\\:\\ 0\\.0017719291296235072\ \(0\)\
\-\ evidence\\:\\ 0\\.0017354319003616404\ \(0\)\
\-\ than\\:\\ 0\\.0017343523275896778\ \(0\)\
\-\ common\\:\\ 0\\.0017321976854813301\ \(0\)\
\-\ who\\:\\ 0\\.0017257694881035648\ \(0\)\
\-\ anterior\\:\\ 0\\.0017047194606992545\ \(0\)\
\-\ over\\:\\ 0\\.0016852382572734026\ \(0\)\
\-\ metastatic\\:\\ 0\\.0016662350144198996\ \(0\)\
\-\ abdominal\\:\\ 0\\.001654468813417595\ \(0\)\
\-\ consistent\\:\\ 0\\.0016230040812015517\ \(0\)\
\-\ bilateral\\:\\ 0\\.0016063653983845424\ \(0\)\
\-\ tissue\\:\\ 0\\.0015688777602266412\ \(0\)\
\-\ imaging\\:\\ 0\\.0015507930476031005\ \(0\)\
\-\ \\%\\:\\ 0\\.0015440131939163499\ \(0\)\
\-\ most\\:\\ 0\\.0015281449587359226\ \(0\)\
\-\ small\\:\\ 0\\.0015248453016120207\ \(0\)\
\-\ present\\:\\ 0\\.0014949719240369332\ \(0\)\
\-\ lower\\:\\ 0\\.0014886615564398628\ \(0\)\
\-\ \\.\\:\\ 0\\.0014848760257604174\ \(0\)\
\-\ \\'s\\:\\ 0\\.0014593699600054571\ \(0\)\
\-\ exam\\:\\ 0\\.001454092904685932\ \(0\)\
\-\ after\\:\\ 0\\.001369481953996284\ \(0\)\
\-\ presents\\:\\ 0\\.0013521644426862324\ \(0\)\
\-\ seen\\:\\ 0\\.0013079997018339972\ \(0\)\
\-\ has\\:\\ 0\\.0012429899074316638\ \(0\)\
\-\ male\\:\\ 0\\.001196905916256757\ \(0\)\
\-\ history\\:\\ 0\\.0009141863189055643\ \(0\)\
\-\ at\\:\\ 0\\.0008967956257410016\ \(0\)\
\-\ no\\:\\ 0\\.0006664943072841224\ \(0\)\
